Global First .. NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311 ...Middle East

SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for its...

Hence then, the article about global first nmpa accepts ind application for mabwell s innovative lilrb4 cd3 tce bispecific antibody 6mw5311 was published today ( Thursday 16/04/2026 - 06:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Global First .. NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311 )

Also on site :

• This Fan-Favorite Cookie Brand Is Expanding Its Gluten-Free Line
• Walmart’s 'Supportive' Water Shoes Are on Sale for $22, and Shoppers Say They’re  the 'Most Comfortable' Shoes
• Costco Shoppers Are Revealing Their Best Membership Secrets And We’re Taking Notes